AIMD

Ainos is a development-stage company dressed up as two ambitious platforms — the AI Nose scent-digitization sensor and the VELDONA interferon therapeutics — but the numbers say pre-commercial. FY2025 revenue was $124K (of which the filing details $123,360 from AI Nose and $797 from pet supplements) against a net loss of $14.8M and an operating loss of $13.99M. That is a net margin of -11,897% and an operating margin of -11,268%; the business spends roughly 113x its revenue to run. Revenue is also erratic, not a ramp: $595K (FY21) → $3.52M (FY22) → $122K (FY23) → $20.7K (FY24) → $124K (FY25). The '+499% YoY growth' is optical noise off a near-zero base, not durable traction.

The balance sheet is the disqualifier. Cash fell 89.3% to just $417K while the company burned $4.61M in operating cash flow — well under one quarter of runway on hand. Stockholders' equity halved to $7.56M, retained earnings are -$67.5M, and liabilities/equity sits at 1.76x. Management states plainly it is 'dependent on obtaining… necessary funding from outside sources, including… the issuance of securities,' and that the accumulated deficit 'will increase significantly.' With shares outstanding down 52.9% YoY (consistent with a reverse split) and a $13.6M market cap, near-term survival almost certainly requires dilutive equity raises at depressed prices — a direct transfer of value away from current holders.